Leif Bertilsson

22.7k total citations · 3 hit papers
292 papers, 17.5k citations indexed

About

Leif Bertilsson is a scholar working on Pharmacology, Psychiatry and Mental health and Oncology. According to data from OpenAlex, Leif Bertilsson has authored 292 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pharmacology, 62 papers in Psychiatry and Mental health and 61 papers in Oncology. Recurrent topics in Leif Bertilsson's work include Pharmacogenetics and Drug Metabolism (135 papers), Pharmacological Effects and Toxicity Studies (44 papers) and Neurotransmitter Receptor Influence on Behavior (36 papers). Leif Bertilsson is often cited by papers focused on Pharmacogenetics and Drug Metabolism (135 papers), Pharmacological Effects and Toxicity Studies (44 papers) and Neurotransmitter Receptor Influence on Behavior (36 papers). Leif Bertilsson collaborates with scholars based in Sweden, Germany and United States. Leif Bertilsson's co-authors include Marja‐Liisa Dahl, Magnus Ingelman‐Sundberg, Folke Sjöqvist, Gunnel Tybring, Marie Åsberg, Eleni Aklillu, Inger Johansson, Torbjörn Tomson, Juliette Säwe and Conny Nordin and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Leif Bertilsson

285 papers receiving 16.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

2006 562 citations Leif Bertilsson, Magnus Ingelman‐Sundberg et al. Clinical Pharmacology & Therapeutics profile →
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

1993 504 citations Leif Bertilsson, Folke Sjöqvist et al. profile →
"Serotonin Depression"—A Biochemical Subgroup Within the Affective Disorders?

1976 489 citations Leif Bertilsson et al. profile →

Peers

Countries citing papers authored by Leif Bertilsson

Since Specialization

Citations

This map shows the geographic impact of Leif Bertilsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leif Bertilsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leif Bertilsson more than expected).

Fields of papers citing papers by Leif Bertilsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leif Bertilsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leif Bertilsson. The network helps show where Leif Bertilsson may publish in the future.

Co-authorship network of co-authors of Leif Bertilsson

This figure shows the co-authorship network connecting the top 25 collaborators of Leif Bertilsson. A scholar is included among the top collaborators of Leif Bertilsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leif Bertilsson. Leif Bertilsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients 2018 ·BMC Pharmacology and Toxicology ·(unknown), Abdul Rashid Qureshi, Olof Heimbürger, Bengt Lindholm, Ulf Diczfalusy, Björn Anderstam, Leif Bertilsson, Peter Stenvinkel	11
2	UGT1A43 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems 2012 ·Clinical Pharmacology & Therapeutics* ·Tore Haslemo, Irena Loryan, N. Ueda, Buster Mannheimer, Leif Bertilsson, Magnus Ingelman‐Sundberg, Espen Molden, Erik Eliasson	28
3	4β‐Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half‐life of elimination after induction with rifampicin 2008 ·British Journal of Clinical Pharmacology ·Ulf Diczfalusy, Kajsa P. Kanebratt, Eva Bredberg, Tommy B. Andersson, Ylva Böttiger, Leif Bertilsson	107
4	CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels 2008 ·European Journal of Clinical Pharmacology ·Filip Josephson, Leif Bertilsson, Ylva Böttiger, Leo Flamholc, Magnus Gisslén, Vidar Ormaasen, Anders Sönnerborg, Ulf Diczfalusy	54
5	Genetic polymorphism of cytochrome P450s and P‐glycoprotein in the Finnish population 2007 ·Fundamental and Clinical Pharmacology ·(unknown), Anders Rane, Stefan Lundgren, Leif Bertilsson, Kari Laine	27
6	Individualized Medicine - Implementation of Pharmacogenetic Diagnostics in Antidepressant Drug Treatment of Major Depressive Disorders 2003 ·Pharmacopsychiatry ·Julia Kirchheiner, Leif Bertilsson, Henrik Bruus, Anders Wolff, I Roots, Miroslav Bauer	45
7	Interferon‐β treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity 2003 ·British Journal of Clinical Pharmacology ·Karin Hellman, Ewa M. Roos, (unknown), (unknown), Lars L. Gustafsson, Leif Bertilsson, S. Fredrikson	5
8	Antiepileptic Drugs Increase Plasma Levels of 4β-Hydroxycholesterolin Humans 2001 ·Journal of Biological Chemistry ·Karl Bodin, Lionel Brétillon, (unknown), Leif Bertilsson, Ulrika Broomé, Curt Einarsson, Ulf Diczfalusy	198
9	Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders 2000 ·Alimentary Pharmacology & Therapeutics ·(unknown), Leif Bertilsson, Mats Stridsberg, A. Kjellin, Sven Mårdh, Rein Seensalu	30
10	Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P 450 CYP1A2 and CYP2C19 hydroxylate melatonin 2000 ·European Journal of Clinical Pharmacology ·Christer von Bahr, (unknown), N. Yasui, Gunnel Tybring, Leif Bertilsson, Sven Röjdmark	74
11	Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin* 1997 ·Clinical Pharmacology & Therapeutics ·Ylva Böttiger, Gunnel Tybring, (unknown), Leif Bertilsson	73
12	Quantitation of N-terminally extended tachykinins in cerebrospinal fluid from healthy subjects 1994 ·Regulatory Peptides ·Gudrun Toresson, Ernst Brodin, (unknown), Conny Nordin, (unknown), Leif Bertilsson	3
13	N-terminally extended tachykinins in human cerebrospinal fluid 1993 ·Regulatory Peptides ·Gudrun Toresson, Ernst Brodin, Leif Bertilsson	6
14	INTERETHNIC DIFFERENCES IN DRUG OXIDATION. IMPLICATIONS FOR THE UTILIZATION OF ANTIDEPRESSANTS AND NEUROLEPTICS 1992 ·Clinical Neuropharmacology ·(unknown), Inger Johansson, Qun‐Ying Yue, Juliette Säwe, Leif Bertilsson, Magnus Ingelman‐Sundberg, Folke Sjöqvist	2
15	Nonstereoselective Disposition of Ethosuximide in Humans 1990 ·Therapeutic Drug Monitoring ·Tomás Villén, Leif Bertilsson, Folke Sjöqvist	17
16	Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings 1989 ·Clinical Pharmacology & Therapeutics ·(unknown), Anders Lidén, Christina Alm, Conny Nordin, Leif Bertilsson	135
17	Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype 1989 ·Clinical Pharmacology & Therapeutics ·Leif Bertilsson, (unknown), Emílio J. Sanz, Gunnel Tybring, Juliette Säwe, Tomás Villén	209
18	Alprazolam Does Not Inhibit the Metabolism of Nortriptyline in Depressed Patients of Inhibit the Metabolism of Desipramine in Human Liver Microsomes 1988 ·Therapeutic Drug Monitoring ·Leif Bertilsson, Anna Åberg‐Wistedt, Anders Lidén, Koichi Otani, Edoardo Spina	13
19	Formation of a Quaternary N‐Glucuronide of Amitriptyline in Human Liver Microsomes 1987 ·Pharmacology & Toxicology ·(unknown), Leif Bertilsson	19
20	Metabolism of various drugs in subjects with different debrisoquine and sparteine oxidation phenotypes 1982 ·British Journal of Clinical Pharmacology ·Leif Bertilsson, Michel Eichelbaum, Britt Mellström, Juliette Säwe, Folke Sjöqvist	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact